Format

Send to

Choose Destination
See comment in PubMed Commons below
J Clin Invest. 2013 Jun;123(6):2355-7.

Targeting immunosuppression for cancer therapy.

Author information

1
Barts Cancer Institute, John Vane Science Centre, London, United Kingdom.

Abstract

Failing immunity has been acknowledged for its contribution to cancer development and progression. Recent clinical findings have provided payoffs for significant preclinical evaluation and refinement over the last 20 years, but many questions remain to be answered. In this issue of the JCI, Marabelle et al. describe a novel method for targeting the Tregs that infiltrate tumors, demonstrating that dampening the tumor immunosuppressive environment while activating innate antitumor immunity may be an effective approach to cancer treatment.

PMID:
23728169
PMCID:
PMC3668808
DOI:
10.1172/JCI69999
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for American Society for Clinical Investigation Icon for PubMed Central
    Loading ...
    Support Center